{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:59:43Z","timestamp":1791910783174,"version":"4.3.4"},"reference-count":42,"publisher":"Elsevier BV","issue":"14","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":1049,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1016\/j.jacc.2010.06.015","type":"journal-article","created":{"date-parts":[[2010,9,22]],"date-time":"2010-09-22T04:45:49Z","timestamp":1285130749000},"page":"1079-1088","source":"Crossref","is-referenced-by-count":85,"title":["Effects of Varespladib Methyl on Biomarkers and Major Cardiovascular Events in Acute Coronary Syndrome Patients"],"prefix":"10.1016","volume":"56","author":[{"given":"Robert S.","family":"Rosenson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Hislop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Stasiv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Goulder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Waters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2010.06.015_bib1","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2007.02.013","volume":"50","author":"Anderson","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2010.06.015_bib2","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.06.015_bib3","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa042378","article-title":"C-reactive protein levels and outcomes after statin therapy","volume":"352","author":"Ridker","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2010.06.015_bib4","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa0707402","article-title":"Genetically elevated C-reactive protein and ischemic vascular disease","volume":"359","author":"Zacho","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2010.06.015_bib5","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1161\/CIRCULATIONAHA.109.872796","article-title":"Human C-reactive protein does not promote atherosclerosis in transgenic rabbits","volume":"120","author":"Koike","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.06.015_bib6","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/CIRCULATIONAHA.109.907212","article-title":"C-reactive protein and coronary disease: is there a causal link?","volume":"120","author":"Danesh","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.06.015_bib7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s10557-008-6148-1","article-title":"Future role for selective phospholipase A2inhibitors in the prevention of atherosclerotic cardiovascular disease","volume":"23","author":"Rosenson","year":"2009","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jacc.2010.06.015_bib8","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s11886-009-0064-2","article-title":"Secretory phospholipase A2: a multifaceted family of proatherogenic enzymes","volume":"11","author":"Rosenson","year":"2009","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.jacc.2010.06.015_bib9","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.atherosclerosis.2006.08.062","article-title":"Expression of secretory phospholipase A2s in human atherosclerosis development","volume":"196","author":"Kimura-Matsumoto","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2010.06.015_bib10","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1365-2362.2008.01933.x","article-title":"Secretory type II phospholipase A2in culprit coronary lesions is associated with myocardial infarction","volume":"38","author":"Nijmeijer","year":"2008","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jacc.2010.06.015_bib11","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1161\/01.ATV.0000051701.90972.E5","article-title":"Macrophage-expressed group IIA secretory phospholipase A2increases atherosclerotic lesion formation in LDL receptor-deficient mice","volume":"23","author":"Webb","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2010.06.015_bib12","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1161\/01.ATV.0000257133.60884.44","article-title":"Group V secretory phospholipase A2promotes atherosclerosis: evidence from genetically altered mice","volume":"27","author":"Bostrom","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2010.06.015_bib13","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1161\/01.CIR.100.12.1280","article-title":"Circulating levels of secretory type II phospholipase A2predict coronary events in patients with coronary artery disease","volume":"100","author":"Kugiyama","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.06.015_bib14","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1016\/j.ehj.2003.07.003","article-title":"Prognostic value and the changes of plasma levels of secretory type II phospholipase A2in patients with coronary artery disease undergoing percutaneous coronary intervention","volume":"24","author":"Liu","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2010.06.015_bib15","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/S0002-9149(00)01069-9","article-title":"Prognostic value of plasma levels of secretory type II phospholipase A2in patients with unstable angina pectoris","volume":"86","author":"Kugiyama","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2010.06.015_bib16","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s003950070041","article-title":"Level of circulating phospholipase A2in prediction of the prognosis of patients with suspected myocardial infarction","volume":"95","author":"Porela","year":"2000","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.jacc.2010.06.015_bib17","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1161\/ATVBAHA.107.139352","article-title":"Circulating secretory phospholipase A2activity and risk of incident coronary events in healthy men and women: the EPIC-NORFOLK study","volume":"27","author":"Mallat","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2010.06.015_bib18","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1093\/eurheartj\/ehp302","article-title":"Association between type II secretory phospholipase A2plasma concentrations and activity and cardiovascular events in patients with coronary heart disease","volume":"30","author":"Koenig","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2010.06.015_bib19","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0140-6736(09)60403-7","article-title":"Effects of a selective inhibitor of secretory phospholipase A2on low density lipoproteins and inflammatory pathways","volume":"373","author":"Rosenson","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2010.06.015_bib20","article-title":"Randomized trial of an inhibitor of secretory phospholipase A2on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease","author":"Rosenson","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2010.06.015_bib21","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/FJC.0b013e318195bfbc","article-title":"Varespladib (A-002), a secretory phospholipase A2inhibitor, reduces atherosclerosis and aneurysm formation in ApoE\u2013\/\u2013 mice","volume":"53","author":"Fraser","year":"2009","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.jacc.2010.06.015_bib22","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1194\/jlr.M800361-JLR200","article-title":"The synergistic inhibition of atherogenesis in ApoE\u2013\/\u2013mice between pravastatin and the sPLA2inhibitor varespladib (A-002)","volume":"50","author":"Shaposhnik","year":"2008","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacc.2010.06.015_bib23","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0022-2275(20)38488-1","article-title":"Lipolysis of LDL with phospholipase A2alters the expression of selected ApoB-100 epitopes and the interaction of LDL with cells","volume":"29","author":"Kleinman","year":"1988","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacc.2010.06.015_bib24","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1194\/jlr.M400469-JLR200","article-title":"Macrophage-specific expression of group IIA sPLA2results in accelerated atherogenesis by increasing oxidative stress","volume":"46","author":"Tietge","year":"2005","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacc.2010.06.015_bib25","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1161\/01.ATV.0000117174.19078.85","article-title":"Molecular mechanism for changes in proteoglycan binding on compositional changes of the core and the surface of low-density lipoprotein-containing human apolipoprotein B100","volume":"24","author":"Flood","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2010.06.015_bib26","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1161\/01.ATV.17.2.300","article-title":"Localization of nonpancreatic secretory phospholipase A2in normal and atherosclerotic arteries: activity of the isolated enzyme on low-density lipoproteins","volume":"17","author":"Hurt-Camejo","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2010.06.015_bib27","doi-asserted-by":"crossref","first-page":"25913","DOI":"10.1074\/jbc.274.36.25913","article-title":"Phospholipase A2modification of low density lipoproteins forms small high density particles with increased affinity for proteoglycans and glycosaminoglycans","volume":"274","author":"Sartipy","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacc.2010.06.015_bib28","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1161\/01.ATV.21.6.1053","article-title":"Lipolysis of LDL by human secretory phospholipase A2induces particle fusion and enhances the retention of LDL to human aortic proteoglycans","volume":"21","author":"Hakala","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2010.06.015_bib29","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1161\/01.ATV.0000122363.02961.c1","article-title":"Group V sPLA2hydrolysis of low-density lipoprotein results in spontaneous particle aggregation and promotes macrophage foam cell formation","volume":"24","author":"Wooton-Kee","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2010.06.015_bib30","doi-asserted-by":"crossref","first-page":"29116","DOI":"10.1074\/jbc.M202867200","article-title":"Potent modification of low density lipoprotein by group X secretory phospholipase A2is linked to macrophage foam cell formation","volume":"277","author":"Hanasaki","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacc.2010.06.015_bib31","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1161\/01.ATV.19.5.1291","article-title":"Role of group II secretory phospholipase A2in atherosclerosis: 2","volume":"19","author":"Leitinger","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2010.06.015_bib32","doi-asserted-by":"crossref","first-page":"32381","DOI":"10.1074\/jbc.271.50.32381","article-title":"Novel group V phospholipase A2involved in arachidonic acid mobilization in murine P388D1 macrophages","volume":"271","author":"Balboa","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacc.2010.06.015_bib33","doi-asserted-by":"crossref","first-page":"36479","DOI":"10.1074\/jbc.M205399200","article-title":"Group V. phospholipase A,2induces leukotriene biosynthesis in human neutrophils through the activation of group IVa phospholipase A2","volume":"277","author":"Kim","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacc.2010.06.015_bib34","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1084\/jem.20070029","article-title":"Importance of group X-secreted phospholipase A2in allergen-induced airway inflammation and remodeling in a mouse asthma model","volume":"204","author":"Henderson","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.jacc.2010.06.015_bib35","doi-asserted-by":"crossref","first-page":"25936","DOI":"10.1074\/jbc.271.42.25936","article-title":"A heparin-sensitive phospholipase A2and prostaglandin endoperoxide synthase-2 are functionally linked in the delayed phase of prostaglandin d2generation in mouse bone marrow-derived mast cells","volume":"271","author":"Bingham","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacc.2010.06.015_bib36","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1074\/jbc.275.5.3179","article-title":"Exogenously added human group X secreted phospholipase A2but not the group Ib, IIA, and V enzymes efficiently release arachidonic acid from adherent mammalian cells","volume":"275","author":"Bezzine","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacc.2010.06.015_bib37","doi-asserted-by":"crossref","first-page":"26107","DOI":"10.1074\/jbc.M804835200","article-title":"Pro-inflammatory secretory phospholipase A2type IIA binds to integrins alpha V beta 3 and alpha 4 beta 1 and induces proliferation of monocytic cells in an integrin-dependent manner","volume":"283","author":"Saegusa","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacc.2010.06.015_bib38","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1161\/CIRCULATIONAHA.106.628909","article-title":"Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor trial","volume":"114","author":"Morrow","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.06.015_bib39","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1161\/ATVBAHA.108.178681","article-title":"HDL remodeling during the acute phase response","volume":"29","author":"Jahangiri","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2010.06.015_bib40","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.jacc.2007.11.079","volume":"51","author":"Mohler","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2010.06.015_bib41","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1161\/CIRCULATIONAHA.108.771899","article-title":"Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque","volume":"118","author":"Serruys","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.06.015_bib42","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1146\/annurev.biochem.76.062405.154007","article-title":"Biochemistry and physiology of mammalian secreted phospholipases A2","volume":"77","author":"Lambeau","year":"2008","journal-title":"Annu Rev Biochem"}],"updated-by":[{"DOI":"10.1016\/j.jacc.2011.02.004","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2011,3,29]],"date-time":"2011-03-29T00:00:00Z","timestamp":1301356800000}}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109710026409?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109710026409?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T06:34:25Z","timestamp":1636526065000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109710026409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":42,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S0735109710026409"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2010.06.015","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}